Patients with the CYP2C8*3 allele in combination with *1 or another *3 allele may have decreased weight gain and decreased risk of edema when treated with rosiglitazone as compared to patients with the CYP2C8*1/*1. Other genetic and clinical factors may also influence the toxicity to rosiglitazone.